Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 2,910 matching trials from the local directory fallback.

Filters: Baltimore, Maryland Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Adenocarcinoma
Interventions: enzalutamide; Drug
Lead sponsor: Alessa Therapeutics Inc.; Industry
Eligibility: 21 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Fresno, California • San Francisco, California • Chicago, Illinois + 7 more

Conditions: Hand Weakness, Stroke
Interventions: NoNo, occupational therapy - self directed; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Uterine Factor Infertility
Interventions: Imuran, Tacrolimus, Uterine Allotransplantation; Drug · Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2043
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cervical Cancer, Gynaecologic Cancer, Radiation Therapy
Interventions: Intensity Modulated Proton Therapy (IMPT), Volume Modulated Arc Therapy (VMAT); Radiation
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 5
States / cities: Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more

Conditions: Giant Cell Arteritis (GCA)
Interventions: Discontinue Tocilizumab, Tocilizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 50 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: CBD, Nicotine Dependence, Stress, Tobacco Smoking
Interventions: Epidiolex; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma
Interventions: Beta Blocker, Brillouin Microscopy, Prostaglandin Analogue -Containing IOP-Lowering Therapy; Drug · Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Neoplasms
Interventions: Capecitabine, Carboplatin, Gemcitabine, Iza-bren, Nab-paclitaxel, Paclitaxel; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Cerritos, California • Long Beach, California + 35 more

Conditions: Microbial Colonization, Microbial Transplant, Pediatric Infection, S. Aureus Colonization, Staphylococcal Aureus Infection
Interventions: Nasal Microbiota Transplant (NMT), Placebo; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 0 Years to 60 Years
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lung Transplant
Interventions: Belumosudil, Placebo for Belumosudil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 8 more

Conditions: Asthma in Children
Interventions: Asthma CHAMPS Wait List Control, Asthma CHAMPS full program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cognitive Impairment, Stroke, Stroke Sequelae
Interventions: Anodal transcranial Direct Current Stimulation (A-tDCS), Sham Intervention; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peripartum Cardiomyopathy, Postpartum
Interventions: Bromocriptine, Guideline Directed Medical Therapy for Heart Failure (GDMT), Placebo, Rivaroxaban, Second Placebo; Drug
Lead sponsor: Dennis M. McNamara, MD, MS; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 64
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more

Conditions: Barrett's Esophagus, Esophageal Neoplasm
Interventions: Balloon Capsule Device, Endoscopy; Device · Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2028
U.S. locations: 10
States / cities: Baltimore, Maryland • Rochester, Minnesota • St Louis, Missouri + 5 more

Conditions: Knee Osteoarthristis
Interventions: Bright Light therapy via the Re-Timer®, Cognitive-Behavioral Therapy for Insomnia, Negative Ion exposure via IonMi Device, Sleep / Knee Osteoarthritis Education; Device · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Baltimore, Maryland • Chestnut Hill, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Dulaglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 41
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Lung Transplant Failure, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant; Infection or Inflammation
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 14 more

Conditions: Non-muscle Invasive Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Superficial Bladder Cancer
Interventions: EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy); Drug
Lead sponsor: enGene, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 50
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more

Conditions: Myeloproliferative Neoplasms
Interventions: INCA035784; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Phoenix, Arizona • Palo Alto, California • Denver, Colorado + 9 more

Conditions: Breast Reconstruction
Interventions: ARTIA Reconstructive Tissue Matrix; Device
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 20 more

Conditions: Small Cell Lung Cancer
Interventions: Amrubicin, Ifinatamab deruxtecan, Lurbinectedin, Topotecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 30
States / cities: Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more

Conditions: Gastrointestinal Cancer, Head and Neck Cancer, Lung Cancer
Interventions: Collection of biological specimens; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: End-Stage Kidney Disease
Interventions: Hemodialysis thrice weekly, Hemodialysis twice weekly; Other · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 10
States / cities: Jacksonville, Florida • Atlanta, Georgia • Baltimore, Maryland + 7 more

Search by objective public record fields.

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Self-Administered Gaming and Exercise at Home (SAGEH)

Uterus Transplantation to Treat Infertility

GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Effects of Cannabidiol on Stress and Nicotine Withdrawal

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Implementation of Asthma Community Home and School Management Program (Asthma CHAMPS)

TDCS to Improve Post-Stroke Cognitive Impairment

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Sleep TO Prevent Post-surgical Pain

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

Incremental Hemodialysis: The TwoPlus Trial